PD-217014

PD-217014 is a small molecule drug developed by Pfizer as a potent ligand of the alpha(2)delta (α2δ) subunit of voltage-gated calcium channels. It is structurally related to gabapentin and pregabalin, acting as an analog of gamma-Aminobutyric acid (GABA). The compound was designed to provide visceral analgesic activity with higher potency and efficacy than gabapentin. Its mechanism involves antagonism or modulation at the α2δ subunit, which reduces calcium influx in neurons and thereby decreases neurotransmitter release associated with pain signaling. PD-217014 advanced to phase II clinical trials for indications including overactive bladder (OAB), irritable bowel syndrome (IBS), postherpetic neuralgia, and pain; however, all development was discontinued due to factors such as complex synthesis compared to other analogues[1][3][4][5][7].

Other names

444088-20-4UNII-K2T93E812GUNII-K-2T93E812GUNII-K 2T93E812GK2T93E812GK-2T93E812GK 2T93E812G